{"id":33384,"date":"2018-11-20T16:22:49","date_gmt":"2018-11-20T21:22:49","guid":{"rendered":"http:\/\/parkinsonpost.com\/?p=1917"},"modified":"2018-11-20T16:22:49","modified_gmt":"2018-11-20T21:22:49","slug":"reining-in-impulsivity","status":"publish","type":"post","link":"https:\/\/archiveparkinson.thedev.ca\/fr\/reining-in-impulsivity\/","title":{"rendered":"Reining in impulsivity"},"content":{"rendered":"
\"\"

Melanie Tremblay
Postdoctoral
Research Fellow
University of Toronto<\/span><\/p><\/div>\n

Up to 20 percent of people with Parkinson\u2019s disease who take a new class of drugs to help reduce their stiffness, shakiness, slowness or unsteadiness have encountered an unwanted side-effect: impulsivity.<\/p>\n

Although the drugs, ropinirole and pramipexole, are effective at reducing motor control problems, the unwanted impulsivity can lead people into destructive behaviours. At the University of British Columbia, neuroscientist Melanie Tremblay, PhD,\u00a0 is investigating the underlying mechanisms and pathways in the brain that are associated with the drug\u2019s impulsivity reactions.<\/p>\n

\u201cPeople develop things like gambling, hypersexuality, binge eating,\u201d Tremblay explains. \u201cIt can be really devastating in those people.\u201d<\/p>\n

Ropinirole and pramipexole work by increasing the release of dopamine in the brain, and serotonin has been implicated in disorders of impulsivity, as well as in Parkinson\u2019s disease. Tremblay is working with animal models to understand the interplay between these two systems in creating impulsivity in response to drug treatment for the disease. She\u2019s also testing the effectiveness of another medication that works on the serotonin system, to see if it can reverse the unwanted impulsivity effects of ropinirole.<\/p>\n

Her goal is to discover a way to either reduce or block the side effects of these useful medications, or to predict who might be particularly vulnerable to the side effects, for example people with less serotonin in their systems. Then doctors could avoid prescribing these drugs to those people.<\/p>\n

\u201cThese drugs are actually very good,\u201d Tremblay says. \u201cWhen they work, they work very well.\u201d<\/p>\n

Alternatively, if Tremblay discovers that another drug could help, doctors might be able to add it to a treatment plan to decrease these side effects.<\/p>\n

Tremblay, who initially wanted to be a psychologist, fell in love with learning about receptors and cellular pathways when she took a course on the biology of the brain during her undergraduate degree.<\/p>\n

\u201cI always like learning about how drugs work,\u201d she says. \u201cThey make me curious.\u201d<\/p>\n

During that research, Tremblay became interested in Parkinson\u2019s disease\u2014and now she hopes her work will lead to new treatment options for people with Parkinson\u2019s.<\/p>\n

Eventually, she\u2019d like to become a professor or work in drug development and drug testing.<\/p>\n

\u201cRight now, since there is no cure (for Parkinson\u2019s), we have the option of giving levodopa or deep brain stimulation, which is really invasive. However I can improve those treatments\u2014that\u2019s my goal for now.\u201d<\/p>\n

Editor\u2019s Note:<\/em><\/strong><\/p>\n

Melanie Tremblay was awarded a Basic Research Fellowship<\/strong> funded by Pedaling for Parkinson\u2019s<\/strong> in 2017. Since 1981, through the generosity of donors including Pedaling for Parkinson\u2019s supporters, Parkinson Canada has invested $29\u00a0million in 552 research projects.<\/p>\n

In 2018, the annual event took place in Parry Sound, Ontario and raised more than $700,000. The ride is supporting five grants through the Parkinson Canada Research Program<\/strong> in the current funding cycle.<\/p>\n